LearnSomething Releases REMS Training Program for Abstral

Mar 14, 2011, 09:52 ET from LearnSomething

TALLAHASSEE, Fla., March 14, 2011 /PRNewswire/ -- LearnSomething today announced the offering of their first Risk Evaluation and Mitigation Strategy(REMS) pharmacy training program for Abstral, an opioid sublingual tablet manufactured by ProStrakan, Inc., and indicated for the management of breakthrough pain in cancer patients.

Pharmacies can now contact a LearnSomething representative to facilitate access to the training course required for enrollment in the Abstral REMS program in order to have Abstral prescriptions filled.

LearnSomething's connectivity technologies enable clients to either host the program on their own server or access it via LearnSomething's network and software.

The Tallahassee-based online education company is also working with industry partners to develop a robust pharmacy education network that will include class-wide REMS programs and upcoming individual programs.

Under guidance from the FDA, the REMS program was instituted to ensure that the benefits of a drug or biological product continue to outweigh the risks to consumers, and to minimize adverse effects.

About LearnSomething

LearnSomething has developed innovative eLearning solutions for pharmacy, grocery and health care industries for more than a decade. Our flexible learning management solutions and services support the online delivery and tracking of CPE and non-credit programs. For more information, visit www.learnsomething.com

SOURCE LearnSomething